Natco Pharma · NSE: NATCOPHARM · BSE: 524816
Q2 FY26 results · Jul–Sep 2025
Natco Pharma reported revenue from operations of ₹1,363.00 crore (down 0.6% from Q2 FY25) and net profit of ₹517.90 crore (down 23.4% from Q2 FY25) for Q2 FY26 (Jul–Sep 2025), on a consolidated basis.
| Item | Q2 FY26 | Q2 FY25 | YoY | Q1 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1,363.00 | 1,371.10 | −0.6% | 1,328.90 | +2.6% |
| Other income | 100.00 | 63.80 | +56.7% | 61.70 | +62.1% |
| Total income | 1,463.00 | 1,434.90 | +2.0% | 1,390.60 | +5.2% |
| Profit before tax | 613.70 | 818.20 | −25.0% | 571.90 | +7.3% |
| Net profit for the period | 517.90 | 676.50 | −23.4% | 480.30 | +7.8% |
| Attributable to shareholders of the company | 518.40 | 677.30 | −23.5% | 480.70 | +7.8% |
| EPS, basic (₹) | 28.94 | 37.81 | −23.5% | 26.84 | +7.8% |
| Net margin (%) | 38.0 | 49.3 | 36.1 |
| Item | Q2 FY26 | Q2 FY25 | YoY | Q1 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1,264.30 | 1,292.60 | −2.2% | 1,192.70 | +6.0% |
| Other income | 93.30 | 51.40 | +81.5% | 59.60 | +56.5% |
| Total income | 1,357.60 | 1,344.00 | +1.0% | 1,252.30 | +8.4% |
| Profit before tax | 586.00 | 796.90 | −26.5% | 542.90 | +7.9% |
| Net profit for the period | 500.90 | 661.10 | −24.2% | 464.10 | +7.9% |
| EPS, basic (₹) | 27.97 | 36.91 | −24.2% | 25.91 | +8.0% |
| Net margin (%) | 39.6 | 51.1 | 38.9 |
Consolidated
- Filed with BSE
- 14 Nov 2025, 15:58 IST
- Board meeting
- 14 Nov 2025
- Period
- 01 Jul 2025 to 30 Sep 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 14 Nov 2025, 15:58 IST
- Board meeting
- 14 Nov 2025
- Period
- 01 Jul 2025 to 30 Sep 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE